Spyre Therapeutics

Yahoo Finance • 13 days ago

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange... Full story

Yahoo Finance • 13 days ago

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, Hi... Full story

Yahoo Finance • 13 days ago

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing da... Full story

Yahoo Finance • 26 days ago

Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30.... Full story

Yahoo Finance • last month

Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?

Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the small-cap stocks that are on fire right now. On April 16, Spyre Therapeutics successfully closed an underwritten public offering, generating ~$463.5 million in gross proceeds. The final t... Full story

Yahoo Finance • last month

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics launches $300M public stock offering

* Spyre Therapeutics (SYRE [https://seekingalpha.com/symbol/SYRE]) has started a $300M underwritten public offering [https://seekingalpha.com/pr/20471165-spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock] of commo... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis treatment. Continue Reading... Full story

Yahoo Finance • 2 months ago

Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears

Cameron Turtle, the chief executive officer of Spyre Therapeutics(NASDAQ:SYRE), reported the direct sale of 15,000 shares of common stock for approximately $740K on April 1, 2026, according to a SEC Form 4 filing. Transaction summary Met... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the sta... Full story

Yahoo Finance • 2 months ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • 2 months ago

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • 3 months ago

VR Adviser Adds Over 1 Million Savara Shares

According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued... Full story

Yahoo Finance • 3 months ago

Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026

Spyre Therapeutics (NASDAQ:SYRE) is one of the 17 biotechnology stocks with more than 50% upside. As of the close of play on February 12, consensus sentiment around Spyre Therapeutics (NASDAQ:SYRE) was strongly bullish. The stock had rece... Full story

Yahoo Finance • 6 months ago

Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended... Full story

Yahoo Finance • 7 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investig... Full story

Yahoo Finance • 7 months ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammato... Full story

Yahoo Finance • 7 months ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational th... Full story